VRTX Quote, Financials, Valuation and Earnings

Eli Lilly & Co. has a net margin of 36.91% compared to Vertex Pharmaceuticals, Inc.'s net margin of 34.4%. Vertex Pharmaceuticals, Inc.'s return on equity of 22.97% beat Eli Lilly & Co.'s return on equity of 104.39%.

Vertex Pharmaceuticals, Inc. has a consensus price target of $530.70, signalling upside risk potential of 11.28%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,211.21 which suggests that it could grow by 19.98%. Given that Eli Lilly & Co. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Eli Lilly & Co. is more attractive than Vertex Pharmaceuticals, Inc..

Vertex Pharmaceuticals, Inc. has a beta of 0.303, which suggesting that the stock is 69.725% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.

Vertex Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.62% to investors and pays a quarterly dividend of $1.73 per share. Vertex Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Vertex Pharmaceuticals, Inc. quarterly revenues are $3.2B, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Vertex Pharmaceuticals, Inc.'s net income of $1.2B is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Vertex Pharmaceuticals, Inc.'s price-to-earnings ratio is 31.10x while Eli Lilly & Co.'s PE ratio is 44.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals, Inc. is 10.19x versus 14.11x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of 36.91% compared to Vertex Pharmaceuticals, Inc.'s net margin of 18.06%. Vertex Pharmaceuticals, Inc.'s return on equity of 22.97% beat Merck & Co., Inc.'s return on equity of 39.63%.

Vertex Pharmaceuticals, Inc. has a consensus price target of $530.70, signalling upside risk potential of 11.28%. On the other hand Merck & Co., Inc. has an analysts' consensus of $126.00 which suggests that it could grow by 3.06%. Given that Vertex Pharmaceuticals, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Vertex Pharmaceuticals, Inc. is more attractive than Merck & Co., Inc..

Vertex Pharmaceuticals, Inc. has a beta of 0.303, which suggesting that the stock is 69.725% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.280, suggesting its less volatile than the S&P 500 by 72.042%.

Vertex Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.68% to investors and pays a quarterly dividend of $0.85 per share. Vertex Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Vertex Pharmaceuticals, Inc. quarterly revenues are $3.2B, which are smaller than Merck & Co., Inc. quarterly revenues of $16.4B. Vertex Pharmaceuticals, Inc.'s net income of $1.2B is lower than Merck & Co., Inc.'s net income of $3B. Notably, Vertex Pharmaceuticals, Inc.'s price-to-earnings ratio is 31.10x while Merck & Co., Inc.'s PE ratio is 16.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals, Inc. is 10.19x versus 4.72x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of 36.91% compared to Vertex Pharmaceuticals, Inc.'s net margin of -121.83%. Vertex Pharmaceuticals, Inc.'s return on equity of 22.97% beat Moderna, Inc.'s return on equity of -29.19%.

Vertex Pharmaceuticals, Inc. has a consensus price target of $530.70, signalling upside risk potential of 11.28%. On the other hand Moderna, Inc. has an analysts' consensus of $41.75 which suggests that it could fall by -16.28%. Given that Vertex Pharmaceuticals, Inc. has higher upside potential than Moderna, Inc., analysts believe Vertex Pharmaceuticals, Inc. is more attractive than Moderna, Inc..

Vertex Pharmaceuticals, Inc. has a beta of 0.303, which suggesting that the stock is 69.725% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.318, suggesting its more volatile than the S&P 500 by 31.821%.

Vertex Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vertex Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

Vertex Pharmaceuticals, Inc. quarterly revenues are $3.2B, which are larger than Moderna, Inc. quarterly revenues of $678M. Vertex Pharmaceuticals, Inc.'s net income of $1.2B is higher than Moderna, Inc.'s net income of -$826M. Notably, Vertex Pharmaceuticals, Inc.'s price-to-earnings ratio is 31.10x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals, Inc. is 10.19x versus 9.98x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of 36.91% compared to Vertex Pharmaceuticals, Inc.'s net margin of -9.34%. Vertex Pharmaceuticals, Inc.'s return on equity of 22.97% beat Pfizer Inc.'s return on equity of 10.84%.

Vertex Pharmaceuticals, Inc. has a consensus price target of $530.70, signalling upside risk potential of 11.28%. On the other hand Pfizer Inc. has an analysts' consensus of $28.56 which suggests that it could grow by 7.18%. Given that Vertex Pharmaceuticals, Inc. has higher upside potential than Pfizer Inc., analysts believe Vertex Pharmaceuticals, Inc. is more attractive than Pfizer Inc..

Vertex Pharmaceuticals, Inc. has a beta of 0.303, which suggesting that the stock is 69.725% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.751%.

Vertex Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.45% to investors and pays a quarterly dividend of $0.43 per share. Vertex Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 126.47% of its earnings as a dividend.

Vertex Pharmaceuticals, Inc. quarterly revenues are $3.2B, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. Vertex Pharmaceuticals, Inc.'s net income of $1.2B is higher than Pfizer Inc.'s net income of -$1.6B. Notably, Vertex Pharmaceuticals, Inc.'s price-to-earnings ratio is 31.10x while Pfizer Inc.'s PE ratio is 19.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vertex Pharmaceuticals, Inc. is 10.19x versus 2.43x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.